LEADER 03395nam  2200517Ia 450 
001 9910957675503321
005 20251117005943.0
010   $a1-60876-345-5
035   $a(CKB)2670000000041771
035   $a(EBL)3018501
035   $a(SSID)ssj0000428798
035   $a(PQKBManifestationID)11323185
035   $a(PQKBTitleCode)TC0000428798
035   $a(PQKBWorkID)10425014
035   $a(PQKB)10059308
035   $a(MiAaPQ)EBC3018501
035   $a(BIP)23628024
035   $a(EXLCZ)992670000000041771
100   $a20080804d2008      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aStatins /$fGunnar N. Holmqvist (editor)
205   $a1st ed.
210   $aNew York $cNova Science Publishers$dc2008
215   $a1 online resource (219 p.)
300   $aDescription based upon print version of record.
311 08$a1-60692-103-7 
320   $aIncludes bibliographical references and index.
327   $aStatin therapy for coronary artery disease beyond lipid lowering effect / Teruo Inoue, Koichi Node -- Side effects of statins in monotherapy / Helmut Sinzinger, Bernhard A. Peskar -- Preliminary findings about the trends of the renal hemodynamics and the proxies of cardiovascular risk during a short course of atorvastatin therapy in essential hypertensives / Luigi Vernaglione -- Beneficial effects of addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions / Hetal D. Shah ... [et al.] -- Non-lipid lowering effects of statins / A. Schmidt -- Statins in the therapy of acute coronary syndrome / Petr Ostadal -- Beneficial effects of addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions / Hetal D. Shah ... [et al.] -- Bad HDL-C responders to statins / Dirk Devroey -- Beneficial effects of statins in systemic lupus erythematosus : molecular mechanism involved / Antonio G. Tristano.
330   $aThis new book focuses on statins which are a relatively new group of drugs used to lower blood cholesterol levels. A high cholesterol level increases a person's risk of having a heart attack or stroke. The long-term use of statins reduces the risk of such an event and can increase the life expectancy of people with a history of heart disease. The statins work by blocking an enzyme in the body that is involved in the production of LDL cholesterol, especially in the liver. This enzyme is known as HMG coenzyme A reductase. The statins are the most effective group of drugs for lowering the levels of LDL cholesterol in the body. Potential side-effects include muscle cramps and gastrointestinal upsets. These are usually resolved on temporarily lowering the dose. Liver enzyme derangements may occur, which generally return to normal after briefly discontinuing the drug. Some report headaches. Other side-effects occur rarely.
606   $aStatins (Cardiovascular agents)
606   $aAnticholesteremic agents
615  0$aStatins (Cardiovascular agents)
615  0$aAnticholesteremic agents.
676   $a615/.718
701   $aHolmqvist$b Gunnar N$01864235
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910957675503321
996   $aStatins$94471011
997   $aUNINA